| CASE REPORT |
|
| Year : 2022 | Volume
: 26
| Issue : 2 | Page : 82-85 |
|
|
Vaccine-induced pityriasis rosea and pityriasis rosea-like Eruptions: A review of literature and a case report of COVID-19 vaccine-induced pityriasis rosea
Eman Almukhadeb1, Faisal A Alghubaywi2, Yousef Alharthi3, Amer Alharbi4
1 College of Medicine, King Saud University; Division of Dermatology, King Khaled University Hospital, Riyadh, Saudi Arabia
2 College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
3 College of Medicine, University of Tabuk, Tabuk, Saudi Arabia
4 College of Medicine, Jouf University, Sakaka, Saudi Arabia
Correspondence Address:
Dr. Faisal A Alghubaywi
8408 Ad Dayha, Al Khaleej, Riyadh 13224 4407
Saudi Arabia
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jdds.jdds_7_22
|
|
|
Pityriasis rosea (PR) is frequently proposed to result from a viral etiology. In line with the current pandemic, COVID-19 vaccines are noticed to trigger PR development. Our patient is a 23-year-old female who developed an itchy skin rash following the Pfizer–BioNTech COVID-19 vaccine. Examination showed one erythematous plaque on the left shoulder and multiple small scaly plaques of similar appearance distributed over the trunk and proximal extremities. The patient was clinically diagnosed, educated, reassured, prescribed topical mometasone ointment and oral chlorpheniramine, and was given a follow-up appointment. We report this case to increase awareness on COVID-19 vaccines as potential triggers of PR.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
